PTCT Ptc Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PTCT

Price (delayed)

$68.44

Market cap

$5.71B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$5.36B

?
Relative Growth: Rel. Growth: 49
Relative Strength: Rel. Strength: 51
Relative Valuation: Rel. Valuation: 14
Relative Profitability: Rel. Profitability: 45

PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust ...

Highlights
Ptc Therapeutics's equity has increased by 20% YoY and by 8% QoQ
The EPS has dropped by 108% year-on-year but it has soared by 74% since the previous quarter
The net income has plunged by 106% YoY but it has soared by 79% from the previous quarter
The company's debt has surged by 79% YoY and by 76% QoQ
The gross margin has declined by 4.2% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ptcbio.com
Peers: FATE VRTX SRPT XNCR

Key stats

What are the main financial stats of PTCT

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
0.63%
1 week
-9.71%
1 month
-17.85%
1 year
31.29%
YTD
-9.9%
QTD
-16.1%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$1.01B
Gross profit
$938.07M
Operating income
$125.6M
Net income
-$38.38M
Gross margin
93%
Net margin
-3.8%
The company's net margin has shrunk by 111% YoY but it has surged by 83% QoQ
The net income has plunged by 106% YoY but it has soared by 79% from the previous quarter
The company's operating income has shrunk by 82% YoY
PTCT's operating margin has dropped by 69% year-on-year

Price vs fundamentals

How does PTCT's price correlate with its fundamentals

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.63
EV/EBIT
45.33
EV/EBITDA
29.62
EV/Sales
5.31
The EPS has dropped by 108% year-on-year but it has soared by 74% since the previous quarter
Ptc Therapeutics's equity has increased by 20% YoY and by 8% QoQ
The price to sales (P/S) is 44% higher than the 5-year quarterly average of 3.9 and 14% higher than the last 4 quarters average of 4.9
Ptc Therapeutics's revenue has decreased by 43% YoY but it has increased by 22% from the previous quarter

Efficiency

How efficient is Ptc Therapeutics business performance
Ptc Therapeutics's ROA has plunged by 105% YoY but it has soared by 81% from the previous quarter
The ROIC has plunged by 90% YoY
The ROS has dropped by 75% year-on-year

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 4.8% less than the total liabilities
The quick ratio rose by 40% since the previous quarter but it has declined by 8% year-on-year
Ptc Therapeutics's current ratio has increased by 39% QoQ but it has decreased by 6% YoY
PTCT's debt to equity has dropped by 124% year-on-year and by 92% since the previous quarter
The company's debt has surged by 79% YoY and by 76% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.